Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHK-Cu

Copper Tripeptide-1, Glycyl-L-Histidyl-L-Lysine Copper, Prezatide Copper

Quick Stats
Studies 149
Trials 1
Score 3
2023 pubmed

Intranasal GHK peptide enhances resilience to cognitive decline in aging mice.

Tucker. Matthew M; Keely. Addison A; Park. Joo Young JY; Rosenfeld. Manuela M; Wezeman. Jackson J; Mangalindan. Ruby R; Ratner. Dan D; Ladiges. Warren W

Key Findings

  • Intranasal GHK‑Cu (15 mg/kg) for 2 months improved spatial memory and learning in 20‑month‑old mice.
  • Treated mice showed lower levels of neuroinflammatory markers compared with saline controls.
  • Axonal damage markers were reduced, indicating less nerve injury in the brain.

Practical Outcomes

  • For biohackers, the study suggests a potential protocol: a daily intranasal GHK‑Cu spray at a dose roughly equivalent to 15 mg/kg (scaled to human weight) could support brain resilience. However, because the data are from mice, anyone interested should start with very low doses, use a medical‑grade atomizer, and monitor cognitive function and any side effects while awaiting human trials.

Summary

Giving old mice a daily nose spray of the copper‑bound peptide GHK (about 15 mg per kilogram of body weight) for two months made them better at maze‑like memory tests and lowered signs of brain inflammation and nerve damage. The results hint that a similar nasal spray could help protect the aging brain, but human studies are still needed.

Abstract

Brain aging and cognitive decline are aspects of growing old. Age-related cognitive impairment entails the early stages of cognitive decline, and is extremely common, affecting millions of older people. Investigation into early cognitive decline as a treatable condition is relevant to a wide range of cognitive impairment conditions, since mild age-related neuropathology increases risk for more severe neuropathology and dementia associated with Alzheimer's Disease. Recent studies suggest that the naturally occurring peptide GHK (glycyl-L-histidyl-L-lysine) in its Cu-bound form, has the potential to treat cognitive decline associated with aging. In order to test this concept, male and female C57BL/6 mice, 20 months of age, were given intranasal GHK-Cu, 15 mg/kg daily, for two months. Results showed that mice treated with intranasal GHK-Cu had an enhanced level of cognitive performance in spatial memory and learning navigation tasks, and expressed decreased neuroinflammatory and axonal damage markers compared to mice treated with intranasal saline. These observations suggest that GHK-Cu can enhance resilience to brain aging, and has translational implications for further testing in both preclinical and clinical studies using an atomizer device for intranasal delivery.

Study Information

Provider

pubmed

Year

2023

Date

2023-11-17T00:00:00.000Z

DOI

10.1101/2023.11.16.567423

References

35